Beacon Biosignals closed an $86 million financing to build a large, standardized brain‑wave database intended to accelerate neurological drug and diagnostic development. The company plans to collect and annotate electrophysiological data at scale to support biomarker discovery, trial enrichment and digital endpoints for conditions such as Alzheimer’s and Parkinson’s disease. Beacon’s raise aims to feed preclinical and clinical programs that require high‑quality neural signal libraries.